Exposure of the elderly to potential nephrotoxic drug combinations in Belgium

Pharmacoepidemiol Drug Saf. 2008 Oct;17(10):1014-9. doi: 10.1002/pds.1641.

Abstract

Purpose: To count in the Belgian ambulatory prescription database Pharmanet, the number of elderly people treated with ACE inhibitors (ACEI) and/or angiotensine receptor blockers (ARB) (+/-diuretics +/- beta-blockers) who eventually also received a prescription of non-steroidal anti-inflammatory drugs (NSAID) or spironolactone.

Method: All prescriptions dispensed in community pharmacies are collected in the Pharmanet database. The data of 2005 were used. Two age groups were studied: 65-79 years (label 1) and 80+ years (label 2). The following chronic treatments (subgroups) were studied: (A) ACEI/ARB; (B) ACEI/ARB + diuretics; (C) ACEI/ARB + spironolactone; (D) ACEI/ARB + beta-blocker + diuretic and (E) ACEI/ARB + beta-blocker + spironolactone.

Results: In 2005, 7.3% of Belgian population was chronically treated with ACEI/ARB. Twenty-five per cent of 65-79 year-old-patients (subgroup A1) and 36.15% of 80+ year-old-patients (subgroup A2) received ACEI/ARB. At least one package of NSAID or spironolactone was prescribed to subgroup A1 in 25.44 and 5.80%, respectively, and to subgroup A2 in 22.04 and 9.89%, respectively. In all studied subgroups and age categories, NSAID were coprecribed in more than 20-35% of cases.

Conclusions: NSAID are frequently prescribed in elderly patients treated with ACEI or ARB in combination with diuretics. Severe renal adverse effects may result in this high-risk population.

Publication types

  • Comparative Study

MeSH terms

  • Acute Kidney Injury / chemically induced*
  • Acute Kidney Injury / epidemiology
  • Aged
  • Aged, 80 and over
  • Angiotensin II Type 1 Receptor Blockers / administration & dosage
  • Angiotensin II Type 1 Receptor Blockers / adverse effects*
  • Angiotensin-Converting Enzyme Inhibitors / administration & dosage
  • Angiotensin-Converting Enzyme Inhibitors / adverse effects*
  • Anti-Inflammatory Agents, Non-Steroidal / administration & dosage
  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects*
  • Belgium / epidemiology
  • Cohort Studies
  • Databases, Factual
  • Drug Therapy, Combination
  • Female
  • Humans
  • Male
  • Risk Factors
  • Spironolactone / administration & dosage
  • Spironolactone / adverse effects*

Substances

  • Angiotensin II Type 1 Receptor Blockers
  • Angiotensin-Converting Enzyme Inhibitors
  • Anti-Inflammatory Agents, Non-Steroidal
  • Spironolactone